GlassScriptPhysician profile
Ravi Rajan
NPI 1831135078
$79,306.50
in general payments reported to CMS, 2019-2025
51 companies · $17K in 2025
The $17K reported for 2025 was more than what 96% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $15K · 2021: $5,510 · 2022: $4,548 · 2023: $7,699 · 2024: $11K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Food and Beverage: $5,777 · Travel and Lodging: $2,450 · Consulting Fee: $1,285 · Honoraria: $400 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,150.00 |
| Food and Beverage | $5,776.71 |
| Travel and Lodging | $2,449.73 |
| Consulting Fee | $1,285.00 |
| Honoraria | $400.00 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $33,370.18 | 2019-2025 | |
| Astellas Pharma US INC | $31,539.38 | 2019-2025 | Xtandi |
| Avyxa Pharma, LLC | $3,644.77 | 2025 | |
| Janssen Biotech, INC. | $1,507.26 | 2019-2025 | Erleada, Rybrevant, Carvykti |
| Procept Biorobotics Corporation | $1,219.59 | 2020-2025 | Aquabeam System |
| Myriad Genetic Laboratories, INC. | $1,212.52 | 2020-2025 | Prolaris |
| Dendreon Pharmaceuticals LLC | $625.76 | 2019-2025 | Provenge |
| Sumitomo Pharma America, INC. | $555.83 | 2023-2025 | Gemtesa, Orgovyx |
| Neotract INC. | $507.25 | 2019-2020 | |
| Bard Peripheral Vascular, INC. | $400.00 | 2023 | |
| Teleflex LLC | $380.81 | 2021-2025 | Urolift, Barrigel |
| Antares Pharma, INC. | $380.38 | 2019-2025 | Xyosted |
| Medtronic USA, INC. | $332.76 | 2019-2020 | |
| Telix Pharmaceuticals | $319.37 | 2025 | Illuccix |
| Medtronic, INC. | $315.60 | 2021-2025 | Interstim, Altaviva |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravi Rajan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.